CN112956689A - Kiwi fruit probiotic composition for improving constipation and application thereof - Google Patents

Kiwi fruit probiotic composition for improving constipation and application thereof Download PDF

Info

Publication number
CN112956689A
CN112956689A CN202110101574.8A CN202110101574A CN112956689A CN 112956689 A CN112956689 A CN 112956689A CN 202110101574 A CN202110101574 A CN 202110101574A CN 112956689 A CN112956689 A CN 112956689A
Authority
CN
China
Prior art keywords
composition
bifidobacterium
kiwi fruit
lactobacillus
bifidobacteria
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN202110101574.8A
Other languages
Chinese (zh)
Inventor
陈丽
孙雨薇
李靖
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanjing Aurora Biotechnology Co ltd
Original Assignee
Nanjing Aurora Biotechnology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanjing Aurora Biotechnology Co ltd filed Critical Nanjing Aurora Biotechnology Co ltd
Priority to CN202110101574.8A priority Critical patent/CN112956689A/en
Publication of CN112956689A publication Critical patent/CN112956689A/en
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus
    • A23V2400/113—Acidophilus
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus
    • A23V2400/123—Bulgaricus
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus
    • A23V2400/125—Casei
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus
    • A23V2400/165—Paracasei
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus
    • A23V2400/169—Plantarum
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus
    • A23V2400/175—Rhamnosus
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/51—Bifidobacterium
    • A23V2400/515—Animalis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/51—Bifidobacterium
    • A23V2400/519—Breve
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/51—Bifidobacterium
    • A23V2400/533—Longum

Abstract

The invention discloses a kiwi fruit probiotic composition for improving constipation and application thereof.

Description

Kiwi fruit probiotic composition for improving constipation and application thereof
Technical Field
The invention relates to a composition, in particular to a composition containing kiwi fruit extract and probiotics.
Background
Constipation means that the number of times of defecation per week is less than 3 times per 3 months, and at least one quarter of defecation is accompanied by dry stool, difficult defecation, incomplete defecation and even the symptom of needing to help defecation by hands. Constipation is a common disease and frequently encountered diseases, the incidence rate of the constipation people in China is on the rise, and investigation shows that the incidence rate of constipation is 3-17%.
Constipation can be divided into two categories according to the etiology: primary constipation and secondary constipation. Primary constipation is caused by various factors such as diet, intestinal hypomotility, living habits, psychology and the like, but is not caused by the disease of the patient, and most of the patients are clinically in the type. Secondary constipation refers to constipation caused by a clear cause of the disease itself, including: the use of drugs, nervous system diseases, intestinal nerve injury, anorectal diseases, etc.
Constipation can not only reduce the life quality of patients, but also induce diseases such as anal fissure, hemorrhoids and the like, and even induce severe consequences such as sudden death caused by cardiovascular and cerebrovascular diseases. At present, treatment modalities are classified into life treatment, drug treatment, biofeedback training, and surgical treatment according to causes of constipation. Although many drugs are used for relieving constipation at present, the pathogenesis of constipation is various, and most drugs are used for relieving symptoms and root causes in a short term.
The current mechanism of the medicine for treating constipation mainly changes the intestinal osmotic pressure to force water to transfer into the intestinal tract or force the intestinal tract to defecate, thereby temporarily relieving the constipation symptom. However, this treatment is prone to dependency and may have major side effects.
In addition, CN112155056A reports a yoghurt for regulating intestinal tracts and a preparation method and application thereof, wherein the yoghurt is prepared from the following raw materials in parts by weight: 90-97 parts of raw milk, and 0.7-5 multiplied by 10 of lactobacillus gasseri8CFU/100 g raw milk, Streptococcus thermophilus (0.1-9) x 1010CFU/100 g raw milk, Lactobacillus bulgaricus (0.1-9) x 1010CFU/100 g raw milk, Lactobacillus acidophilus (0.5-7) x 108CFU/100 g raw milk, Lactobacillus plantarum (0.5-7) x 108CFU/100 g raw milk, lactobacillus paracasei (0.1-9) x 107CFU/100 g of probiotics such as raw milk and prebiotics such as inulin. The yogurt can regulate intestinal flora balance, and prevent constipation and gestational diabetes of overweight and/or obese pregnant women during gestational period.
CN110692885A reports a probiotic health drink for relieving constipation, which comprises mixed probiotics and MCT, wherein the mixed probiotics comprise 5-30% of bifidobacterium longum, 5-30% of bifidobacterium bifidum, 8-35% of lactobacillus rhamnosus, 10-45% of lactobacillus plantarum Lp90, 10-45% of bifidobacterium lactis and 8-35% of bifidobacterium breve in percentage by mass. The probiotic health-care beverage disclosed by the invention is scientific in formula proportioning, promotes the propagation of probiotics in intestinal tracts by bidirectionally regulating the balance between the microecological environment of the intestinal tracts and intestinal flora, inhibits the growth of putrefying bacteria, effectively improves and prevents constipation, enhances the immunity of the intestinal tracts, and can avoid the damage to bodies caused by strong excretion.
The products of the above patents and patent applications containing probiotics have improved constipation, but the improvement effect is not ideal, the cost is high, and the steps for making the products are complicated.
Disclosure of Invention
The invention aims to overcome the defects in the prior art and provides a composition containing kiwi fruit extract and probiotics, wherein the kiwi fruit extract contains dietary fibers and/or actinodin enzyme, and the probiotics contains bifidobacteria.
Further, the dietary fiber contains soluble fiber and insoluble fiber.
Further, the fibers contain pectin.
Further, the Bifidobacterium contains one or more than two of Bifidobacterium animalis, Bifidobacterium breve and Bifidobacterium longum, preferably one or more than two of Bifidobacterium animalis LAFTI B-94, Bifidobacterium breve HA-129 and Bifidobacterium longum HA-13; preferably, bifidobacterium animalis LAFTI B-94: bifidobacterium breve HA-129: bifidobacterium longum HA-135 accounts for 50-80 percent (10-30 percent) and 5-25 percent (5-25 percent).
Further, the probiotics also contain lactobacillus.
Further, the lactobacillus contains one or more of lactobacillus bulgaricus, lactobacillus plantarum, lactobacillus casei, lactobacillus rhamnosus, lactobacillus paracasei and lactobacillus acidophilus.
Further, 6-40 parts of probiotics and 13-33 parts of kiwi fruit extract.
Furthermore, the health food also contains prebiotics, preferably, the prebiotics comprise one or more than two of fructo-oligosaccharide, inulin, xylo-oligosaccharide and galacto-oligosaccharide.
Further, 6-40 parts of probiotics, 13-33 parts of kiwi fruit extract and 1-99 parts of prebiotics.
The invention also provides application of the composition containing the kiwi fruit extract and the probiotics in preparation of medicines and health-care foods for improving constipation.
The invention also provides a preparation method of the kiwi fruit extract and probiotic-containing composition product, which comprises the steps of mixing the kiwi fruit extract and the probiotics and then packaging the finished product.
Preferably, the temperature in all steps of the preparation process does not exceed 50 ℃.
The kiwi fruit extract is an extract obtained by peeling kiwi fruits, and further the kiwi fruit extract is an extract obtained by peeling and removing seeds from the kiwi fruits.
The kiwi fruit extract in the invention can be a residue of kiwi fruit which is subjected to water extraction or low-concentration alcohol extraction, and the residue contains dietary fiber and Actinectin enzyme. Further, the temperature of the water extraction or the alcohol extraction does not exceed 50 ℃. The kiwi fruit extract can also be a product obtained by peeling and crushing kiwi fruits; the kiwi fruit extract can also be a product obtained by peeling and removing seeds of kiwi fruits and crushing; the kiwi fruit extract can also be a residue obtained by peeling and removing seeds of kiwi fruit, crushing, and extracting saccharides, flavonoids, natural vitamins and the like.
The composition comprises dietary fiber in an amount greater than 0.01g/g of the composition, further greater than 0.1g/g of the composition, greater than 0.25g/g of the composition, greater than 0.5g/g of the composition, 0.5g/g of the composition to 0.75g/g of the composition. The dietary fiber content of the composition may also be greater than 0.75g/g of composition.
Actinectin enzyme in the kiwi fruit extract is more than 100AU/g kiwi fruit extract, further more than 500AU/g kiwi fruit extract, more than 1000AU/g kiwi fruit extract, more than 5000AU/g kiwi fruit extract, more than 10000AU/g kiwi fruit extract, more than 15000AU/g kiwi fruit extract, more than 20000AU/g kiwi fruit extract and more than 50000AU/g kiwi fruit extract.
The Actinectin enzyme in the composition is greater than 10AU/g of the composition, further greater than 500AU/g of the composition, greater than 1000AU/g of the composition, greater than 5000AU/g of the composition, greater than 10000AU/g of the composition, greater than 15000AU/g of the composition, greater than 20000AU/g of the composition, greater than 30000AU/g of the composition.
When the applicant researches the defecation effect of the kiwi fruit extract, the kiwi fruit extract is found to be capable of increasing the number of intestinal probiotics; more unexpectedly, the kiwi fruit extract not only can increase the amount of the bifidobacterium short-chain fatty acid, but also can enable the bifidobacterium to generate short-chain fatty acids with different carbon chain lengths, namely, the abundance of the short-chain fatty acids is increased. The short-chain fatty acid is rapidly absorbed by epithelial cells, so that intestinal peristalsis is enhanced, the pH value of an intestinal tract is reduced, the growth of harmful bacteria is inhibited, and the intestinal environment is improved, so that constipation is relieved; the kiwi fruit extract after high-temperature treatment has no effect. Further studies by the applicant could basically establish that the action of the enzyme actin allows bifidobacteria to produce more different short-chain fatty acids, thereby improving the effect of softening the stools.
US10881675B2 Gut health compositions disclose a composition of xylo-oligosaccharide and kiwi fruit extract containing Actinectin enzyme. However, this patent does not add probiotics nor does it find the effect of the actindin enzyme on bifidobacteria.
The viable count of bifidobacteria in the composition is greater than 1 hundred million per gram of the composition, further greater than 10 hundred million per gram of the composition, further greater than 100 hundred million per gram of the composition, further greater than 500 hundred million per gram of the composition, further greater than 1000 hundred million per gram of the composition, further greater than 5000 hundred million per gram of the composition, further greater than 10000 hundred million per gram of the composition.
The viable bacteria amount of the lactobacillus in the composition is more than 1 hundred million per gram of the composition, further more than 10 hundred million per gram of the composition, further more than 100 hundred million per gram of the composition, further more than 500 hundred million per gram of the composition, further more than 1000 hundred million per gram of the composition, further more than 5000 hundred million per gram of the composition, and further more than 10000 hundred million per gram of the composition.
In another embodiment, the amount of viable bacteria of the probiotic in the composition is greater than 1 hundred million per gram of the composition, further greater than 10 hundred million per gram of the composition, further greater than 100 hundred million per gram of the composition, further greater than 500 hundred million per gram of the composition, further greater than 1000 hundred million per gram of the composition, further greater than 5000 hundred million per gram of the composition, further greater than 10000 hundred million per gram of the composition.
Has the advantages that: according to the invention, only the kiwi fruit extract containing dietary fiber and Actinectin enzyme needs to be added, on one hand, the dietary fiber component in the kiwi fruit extract is beneficial to promoting intestinal peristalsis and also used as prebiotics, so that the proliferation of intestinal flora is facilitated, and further the constipation is improved; on the other hand, the Actinectin enzyme in the kiwi fruit extract is beneficial to bifidobacterium to generate different short-chain fatty acids and is also beneficial to improving constipation. Meanwhile, the kiwi fruit extract containing dietary fiber and Actinectin enzyme is very simple and easy to obtain, and other components do not need to be added additionally. According to the invention, the kiwi fruit extract containing dietary fibers and Actinectin enzyme is combined with bifidobacteria, so that the constipation relieving effect is achieved in many aspects. The invention adopts natural components, has no Chinese and western medicine components, and has no adverse side effect.
Description of the drawings:
FIG. 1 is a fatty acid profile of the fermentation of example 1;
FIG. 2 is a fatty acid profile of the fermentation of comparative example 1;
FIG. 3 is a graph showing the intensity of fluorescent signals in intestinal tracts of zebra fish after 72 hours.
Detailed Description
The present invention will be further described with reference to the following examples for facilitating understanding of those skilled in the art, and the description of the embodiments is not intended to limit the present invention.
Example 1
A composition comprising kiwifruit extract comprising dietary fiber and actinodin enzyme and a probiotic comprising bifidobacteria. The dietary fiber is 0.25g/g of the composition, the bifidobacteria is 1000 hundred million/g of the composition, the bifidobacteria comprises animal bifidobacteria LAFTI B-94: bifidobacterium breve HA-129: bifidobacterium longum HA-135 ═ 60%: 20%: 20 percent. The enzyme activity of the Actinectin enzyme is 2000AU/g of the composition.
Example 2
A composition comprising kiwifruit extract comprising dietary fiber and actinodin enzyme and a probiotic comprising bifidobacteria. The dietary fiber is 0.5g/g of the composition, the bifidobacteria is 8000 hundred million/g of the composition, the bifidobacteria comprises animal bifidobacteria LAFTI B-94: bifidobacterium breve HA-129: bifidobacterium longum HA-135 ═ 50%: 25%: 25 percent. The enzyme activity of the Actinidin enzyme is 1000AU/g composition.
Example 3
A composition comprising kiwifruit extract comprising dietary fiber and actinodin enzyme and a probiotic comprising bifidobacteria. The dietary fiber is 0.2g/g of the composition, the bifidobacteria is 1000 hundred million/g of the composition, the bifidobacteria comprises animal bifidobacteria LAFTI B-94: bifidobacterium breve HA-129: bifidobacterium longum HA-135 ═ 20%: 40%: 40 percent. The enzyme activity of the Actinectin enzyme is 500AU/g of the composition.
Example 4
A composition comprising kiwifruit extract comprising dietary fiber and actinodin enzyme and a probiotic comprising bifidobacteria. The dietary fiber is 0.01g/g of the composition, the Bifidobacterium is 1000 hundred million/g of the composition, and the Bifidobacterium is Bifidobacterium animalis LAFTI B-94. The enzyme activity of the Actinectin enzyme is 10000AU/g of the composition.
Example 5
A composition comprising kiwifruit extract comprising dietary fiber and actinodin enzyme and a probiotic comprising bifidobacteria. The dietary fiber is 0.6g/g of the composition, the Bifidobacterium is 10000 hundred million/g of the composition, and the Bifidobacterium is Bifidobacterium breve HA-129. The enzyme activity of the Actinidin enzyme is 20000AU/g composition.
Example 6
A composition comprising kiwifruit extract comprising dietary fiber and actinodin enzyme and a probiotic comprising bifidobacteria. The dietary fiber is 0.5g/g composition, the Bacillus bifidus is 8000 hundred million/g composition, and the Bacillus bifidus is Bifidobacterium longum HA-135. The enzyme activity of the Actinidin enzyme is 10AU/g composition.
Example 7
A composition comprising kiwifruit extract comprising dietary fiber and actinodin enzyme and a probiotic comprising bifidobacteria. The dietary fiber is 0.5g/g of the composition, the bifidobacteria is 8000 hundred million/g of the composition, the bifidobacteria comprises animal bifidobacteria LAFTI B-94: bifidobacterium breve HA-129: bifidobacterium longum HA-135 ═ 50%: 25%: 25 percent. The enzyme activity of the Actinidin enzyme is 1000AU/g composition.
Example 8
A composition comprising kiwifruit extract comprising dietary fiber and actinodin enzyme and a probiotic comprising bifidobacteria. The dietary fiber is 0.25g/g of the composition, the bifidobacteria is 2000 hundred million/g of the composition, the bifidobacteria comprises animal bifidobacteria LAFTI B-94: bifidobacterium breve HA-129: bifidobacterium longum HA-135 ═ 60%: 20%: 20 percent. The enzyme activity of the Actinectin enzyme is 2000AU/g of the composition. The probiotics also contain lactobacillus bulgaricus which is 2000 hundred million/g of the composition.
Example 9
A composition comprising kiwifruit extract comprising dietary fiber and actinodin enzyme and a probiotic comprising bifidobacteria. The dietary fiber is 0.25g/g of the composition, the bifidobacteria is 2000 hundred million/g of the composition, the bifidobacteria comprises animal bifidobacteria LAFTI B-94: bifidobacterium breve HA-129: bifidobacterium longum HA-135 ═ 60%: 20%: 20 percent. The enzyme activity of the Actinectin enzyme is 2000AU/g of the composition. The probiotics also contain lactobacillus plantarum, wherein the lactobacillus plantarum accounts for 2000 hundred million/g of the composition.
Example 10
A composition comprising kiwifruit extract comprising dietary fiber and actinodin enzyme and a probiotic comprising bifidobacteria. The dietary fiber is 0.25g/g of the composition, the bifidobacteria is 2000 hundred million/g of the composition, the bifidobacteria comprises animal bifidobacteria LAFTI B-94: bifidobacterium breve HA-129: bifidobacterium longum HA-135 ═ 60%: 20%: 20 percent. The enzyme activity of the Actinectin enzyme is 2000AU/g of the composition. The probiotics also contain lactobacillus plantarum, wherein the lactobacillus plantarum accounts for 2000 hundred million/g of the composition.
Example 11
A composition comprising kiwifruit extract comprising dietary fiber and actinodin enzyme and a probiotic comprising bifidobacteria. The dietary fiber is 0.25g/g of the composition, the bifidobacteria is 2000 hundred million/g of the composition, the bifidobacteria comprises animal bifidobacteria LAFTI B-94: bifidobacterium breve HA-129: bifidobacterium longum HA-135 ═ 60%: 20%: 20 percent. The enzyme activity of the Actinectin enzyme is 2000AU/g of the composition. The probiotics also contain lactobacillus plantarum, wherein the lactobacillus rhamnosus accounts for 2000 hundred million/g of the composition.
Example 12
A composition comprising kiwifruit extract comprising dietary fiber and actinodin enzyme and a probiotic comprising bifidobacteria. The dietary fiber is 0.25g/g of the composition, the bifidobacteria is 2000 hundred million/g of the composition, the bifidobacteria comprises animal bifidobacteria LAFTI B-94: bifidobacterium breve HA-129: bifidobacterium longum HA-135 ═ 60%: 20%: 20 percent. The enzyme activity of the Actinectin enzyme is 2000AU/g of the composition. The probiotics also contain lactobacillus plantarum, and streptococcus thermophilus is 2000 hundred million/g of the composition.
Example 13
A composition comprising kiwifruit extract comprising dietary fiber and actinodin enzyme and a probiotic comprising bifidobacteria. The dietary fiber is 0.25g/g of the composition, the bifidobacteria is 5000 hundred million/g of the composition, the bifidobacteria comprises animal bifidobacteria LAFTI B-94: bifidobacterium breve HA-129: bifidobacterium longum HA-135 ═ 60%: 20%: 20 percent. The enzyme activity of the Actinectin enzyme is 2000AU/g of the composition. Also contains prebiotics, wherein the prebiotics is fructo-oligosaccharide, and the dosage of the fructo-oligosaccharide is 0.15g/g of the composition.
Example 14
A composition comprising kiwifruit extract comprising dietary fiber and actinodin enzyme and a probiotic comprising bifidobacteria. The dietary fiber is 0.25g/g of the composition, the bifidobacteria is 5000 hundred million/g of the composition, the bifidobacteria comprises animal bifidobacteria LAFTI B-94: bifidobacterium breve HA-129: bifidobacterium longum HA-135 ═ 60%: 20%: 20 percent. The enzyme activity of the Actinectin enzyme is 2000AU/g of the composition. Also contains prebiotics, wherein the prebiotics are fructo-oligosaccharide and xylo-oligosaccharide, the dosage of the fructo-oligosaccharide is 0.1g/g of the composition, and the dosage of the xylo-oligosaccharide is 0.1g/g of the composition.
Comparative example 1
A composition comprises maltodextrin and probiotic bacteria, wherein the bifidobacteria comprises Bifidobacterium animalis LAFTI B-94: bifidobacterium breve HA-129: bifidobacterium longum HA-135 ═ 60%: 20%: 20 percent. The enzyme activity of the Actinectin enzyme is 2000AU/g of the composition. I.e. equal amount of kiwi extract as in example 1 was replaced by maltodextrin.
After 1g of each of example 1 and comparative example 1 was dissolved in 200ml of sterilized water, 1ml of each was pipetted and inoculated into a liquid MRS medium for anaerobic culture. When the strain grows to the later stage of logarithmic phase, taking a proper amount of bacterial liquid to prepare fermentation liquid, and centrifuging at low temperature: 4 ℃,7500rpm,5 min.
Short chain fatty acids in the fermentation broth were determined by Gas Chromatography (GC). Chromatographic conditions are as follows: 6890N Agilent gas chromatograph, HP-INNOWAX (30m × 0.25mm × 0.25 μm) capillary column, Flame Ionization Detector (FID), flow rate of carrier gas (N2) 19.0mL/min, and flow rates of air, hydrogen, and nitrogen 260, 30, and 30mL/min, respectively. The initial column temperature was 100 deg.C, held for 1min, and the column temperature was increased to 180 deg.C at a rate of 5 deg.C/min and held for 4 min. The internal standard is 2-ethyl butyric acid, 0.3mg/mL 2-ethyl butyric acid solution is prepared by 0.2M hydrochloric acid solution, mixed with a sample 1:1(v/v), and subjected to gas chromatography detection after passing through a 0.45-micron filter membrane.
Comparing the map of the example 1 with the map of the comparative example 1, the added kiwi fruit extract can improve the amount of fatty acid of a probiotic fermentation product and simultaneously improve the richness of short-chain fatty acid.
Animal experiments: 210 tails of 5dpf wild type AB strain zebra fish were randomly selected from the petri dish and fed with nile red as a fluorescent indicator of the contents of the intestine. Nile red treatment was performed for 16h and eluted, and randomly grouped into well plates with 30 tails per well (i.e., per experimental group) and a capacity of 3mL per well. Taking the compositions of the example 1 and the comparative example 1, respectively carrying out water-soluble dilution so that the probiotic concentration of the bathed zebra fish is 107CFU/mL, a concentration control group was additionally provided, and the concentration was further diluted by one-fold to make the probiotic concentration of bathed zebrafish 5X 10 by using the same formulation as in example 16CFU/mL. At the same time, a model control group (zebrafish treated with nile red only) was set with a volume of 3mL per well. After each group is treated for 72 hours, 10 zebra fish of each group are randomly picked up and photographed under a fluorescence microscope, image analysis is carried out by NIS-Elements D3.10 advanced image processing software, data are collected, the intensity (S) of the zebra fish intestinal fluorescence signal is counted, and the bowel relaxing effect of the embodiment and the comparative example is evaluated according to the statistical analysis result of the intensity of the zebra fish intestinal fluorescence signal. Statistical treatment results are expressed as mean ± SE. The calculation formula of the bowel relaxing effect is as follows:
the efficacy of relaxing bowel (%) - (S (model control group) -S (test article group)/S (model control group) × 100%
And (3) measuring results:
TABLE 1 intensity of fluorescent signal of zebra fish intestinal tract after 72 hours of treatment of each experimental group
Figure BDA0002915908550000121
The effect of example 1 on relaxing bowel of zebra fish is higher than that of comparative example 1. The zebrafish of example 1 showed almost no significant fluorescence, and the fluorescence of the zebrafish was also relatively weak in the diluted group.
And (4) test conclusion: the kiwi fruit extract added in the embodiment can improve the effect of relaxing bowel of the composition.
It will be understood by those skilled in the art that, unless otherwise defined, all terms (including technical and scientific terms) used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. It will be further understood that terms, such as those defined in commonly used dictionaries, should be interpreted as having a meaning that is consistent with their meaning in the context of the prior art and will not be interpreted in an idealized or overly formal sense unless expressly so defined herein.
It should be understood that the above detailed description of the technical solution of the present invention with the help of preferred embodiments is illustrative and not restrictive. On the basis of reading the description of the invention, a person skilled in the art can modify the technical solutions described in the embodiments, or make equivalent substitutions for some technical features; and such modifications or substitutions do not depart from the spirit and scope of the corresponding technical solutions of the embodiments of the present invention.

Claims (10)

1. A composition characterized by: comprises kiwi fruit extract and probiotics, wherein the kiwi fruit extract contains dietary fiber and/or Actinectin enzyme, and the probiotics contains bifidobacteria.
2. The composition of claim 1, wherein: the dietary fiber contains water-soluble fiber and insoluble fiber.
3. The composition of claim 1, wherein: the fibers contain pectin.
4. The composition of claim 1, wherein: the Bifidobacterium contains one or more of Bifidobacterium animalis, Bifidobacterium breve and Bifidobacterium longum, preferably one or more of Bifidobacterium animalis LAFTI B-94, Bifidobacterium breve HA-129 and Bifidobacterium longum HA-13; preferably, bifidobacterium animalis LAFTI B-94: bifidobacterium breve HA-129: bifidobacterium longum HA-135 accounts for 20-80 percent (10-40 percent) and 5-40 percent (5-40 percent).
5. The composition according to claim 1, characterized in that: the probiotic bacteria further comprise Lactobacillus or lactococcus.
6. The composition according to claim 5, characterized in that: the lactobacillus contains one or more of Lactobacillus bulgaricus, Lactobacillus plantarum, Lactobacillus casei, Lactobacillus rhamnosus, Lactobacillus paracasei, Lactobacillus acidophilus and Streptococcus thermophilus.
7. The composition according to claim 1, characterized in that: 6-40 parts of probiotics and 13-33 parts of kiwi fruit extract.
8. The composition according to claim 1, characterized in that: also contains prebiotics, preferably, prebiotics include one or more of fructo-oligosaccharide, inulin, xylo-oligosaccharide, and galacto-oligosaccharide.
9. The composition according to claim 8, characterized in that: 6-40 parts of probiotics, 13-33 parts of kiwi fruit extract and 40-66 parts of prebiotics.
10. Use of a composition according to any one of claims 1 to 9 for the preparation of a pharmaceutical or nutraceutical product for the amelioration of constipation.
CN202110101574.8A 2021-01-26 2021-01-26 Kiwi fruit probiotic composition for improving constipation and application thereof Withdrawn CN112956689A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110101574.8A CN112956689A (en) 2021-01-26 2021-01-26 Kiwi fruit probiotic composition for improving constipation and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202110101574.8A CN112956689A (en) 2021-01-26 2021-01-26 Kiwi fruit probiotic composition for improving constipation and application thereof

Publications (1)

Publication Number Publication Date
CN112956689A true CN112956689A (en) 2021-06-15

Family

ID=76272493

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202110101574.8A Withdrawn CN112956689A (en) 2021-01-26 2021-01-26 Kiwi fruit probiotic composition for improving constipation and application thereof

Country Status (1)

Country Link
CN (1) CN112956689A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113632841A (en) * 2021-10-14 2021-11-12 北京三元食品股份有限公司 Compound yogurt with constipation improving effect, and preparation method and application thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040058025A1 (en) * 2000-03-21 2004-03-25 Donaldson Bruce William Digestive/laxative compositions
CN108740251A (en) * 2018-06-15 2018-11-06 广东燕岭生命科技股份有限公司 A kind of probiotic gel candy and preparation method thereof improving constipation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040058025A1 (en) * 2000-03-21 2004-03-25 Donaldson Bruce William Digestive/laxative compositions
CN108740251A (en) * 2018-06-15 2018-11-06 广东燕岭生命科技股份有限公司 A kind of probiotic gel candy and preparation method thereof improving constipation

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113632841A (en) * 2021-10-14 2021-11-12 北京三元食品股份有限公司 Compound yogurt with constipation improving effect, and preparation method and application thereof

Similar Documents

Publication Publication Date Title
Wang et al. Bifidobacteria exert species-specific effects on constipation in BALB/c mice
Guan et al. Influence of probiotic fermented fruit and vegetables on human health and the related industrial development trend
JP6796070B2 (en) Foods and drinks containing indigestible components and hydrogen gas producing agents in the large intestine
CN108741083A (en) Promote the neutral human milk oligosaccharides of beneficial bacteria growth
CN110892935A (en) Bifidobacterium lactis for treating constipation and diarrhea and application thereof
TW202002963A (en) Compositions and methods for biosynthetic preparation of UROLITHIN compounds and use thereof
WO2022206300A1 (en) Composition capable of facilitating defecation and use thereof
US11045509B2 (en) Tributyrin compositions and methods therefor
US20230172248A1 (en) Novel lactic acid bacteria having excellent immune function enhancement effect, and food composition, health functional food composition and probiotics comprising same
CN112617182B (en) Plant enzyme composition for weight management and preparation method thereof
Ouwehand et al. Probiotic fermented foods and health promotion
Selvamani et al. Efficacy of probiotics-based interventions as therapy for inflammatory bowel disease: a recent update
CA2908032A1 (en) Composition containing bacterium belonging to genus lactobacillus
KR20180056972A (en) Composition comprising a strain having formic acid producing ability for the preventing or treatment of obesity, or obesity-realated metabolic syndrome
CN106659747A (en) Use of lactobacillus rhamnosus for promoting recovery of the intestinal microbiota diversity after dysbiosis
KR20210156445A (en) Composition for improving intestinal environment containing Vaccinium uliginosum berry powder or extract of Vaccinium uliginosum berry and method for preparation thereof
WO2017047777A1 (en) Serotonin deficiency amelioration agent for after stress-load release
WO2021109879A1 (en) Composition having wholesome personalized intestinal flora diversity function and application
EP4213864A1 (en) Parabacteroides distasonis strains for use thereof in the treatment and prevention of gastrointestinal diseases and of disorders associated with gastrointestinal diseases
CN112956689A (en) Kiwi fruit probiotic composition for improving constipation and application thereof
US11478525B2 (en) Method for promoting growth of Akkermansia muciniphila using musa ferments
Jin et al. A randomized, double-blind, controlled human study: The efficacy of exopolysaccharides in milk fermented by Weissella confusa VP30 (VP30-EPS) to ameliorate functional constipation
US20230310519A1 (en) Use of adlercreutzia bacteria for the treatment of inflammatory diseases
Sivieri et al. Synbiotic yogurts and the elderly
TW202202160A (en) Composition for facilitating defecation and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WW01 Invention patent application withdrawn after publication
WW01 Invention patent application withdrawn after publication

Application publication date: 20210615